StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 27 Sept, 19:05 UTC

This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a…

policyscience

Sources

• T2StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly SuitFierce Biotech / Fierce Healthcare / MedCity / GEN27 Sept, 19:05